Hormonal shifts include changes in menstrual patterns, ovulation timing, or mood linked to peptides that affect endocrine pathways
Clinical trial data on semaglutide and tirzepatide has repeatedly shown that a meaningful share of total weight lost on these medications is lean mass rather than fat mass, with figures in published research and clinical commentary commonly cited in the range of roughly a quarter to nearly forty percent of total weight lost, depending on the study population, age, baseline muscle mass, and whether participants were doing any resistance training at all
Patients with genetic variants linked to altered nutrient absorption may benefit from more frequent B12 monitoring or proactive intramuscular dosing from treatment onset, rather than waiting for symptomatic depletion
P., Zhou, Z
(2021) 372:m4573
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from approved agents such as semaglutide and tirzepatide